Ablynx: ABLYNX WILL ANNOUNCE ITS 2017 HALF YEAR RESULTS WITH WEBCAST ON 24 AUGUST 2017

GHENT, Belgium, 17 August 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] will report its 2017 half year financial results and year-to-date business update on Thursday 24 August 2017 at 7.00 am CET.

The Ablynx management team will host a conference call on Thursday 24 August 2017 at 4.00 pm CET/10.00 am ET, which will be webcast live and may be accessed by clicking here (http://edge.media-server.com/m/p/mfu9roax).

If you would like to participate in the Q&A session, please dial [phone] and use confirmation code 7237205.

Shortly after the call, a replay of the webcast and copy of the presentation will be available on the Ablynx website under http://www.ablynx.com/news/events-presentations/ (http://www.ablynx.com/news/events-presentations/).

About Ablynx

Ablynx (http://www.ablynx.com/) is a biopharmaceutical company engaged in the development of Nanobodies (http://www.ablynx.com/technology-innovation/understanding-nanobodies/), proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes (http://www.ablynx.com/rd-portfolio/overview/) in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com (http://www.ablynx.com).

For more information, please contact
Ablynx:
Dr Edwin Moses
CEO
t:   [phone]
m: [phone]
e:  [e-mail] (mailto:[e-mail])

Lies Vanneste
Director Investor Relations
t:   [phone]
m: [phone]
e:  [e-mail] (mailto:[e-mail])

Follow us on Twitter @AblynxABLX (https://twitter.com/AblynxABLX)

pdf version of the press release (http://hugin.info/137912/R/2127544/812446.pdf)

---

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ablynx via Globenewswire